2 recruiting, 1 completed, 1 not yet recruiting. 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Ventilator-associated Bacterial Pneumonia (VABP): new trials by email Literature Review of Ventilator-associated Bacterial Pneumonia (VABP) trials Research Report on Ventilator-associated Bacterial Pneumonia (VABP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia YK-1169, Ceftazidime-avibactam Injection - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 3 | Not yet recruiting | Nanjing Yoko Biomedical Co., Ltd. | 590 | 2026-06-04 | 2026-06-08 |
| ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia ASK0912 for Injection, Polymyxin B Sulfate for Injection - Ventilator-associated Bacterial Pneumonia (VABP), Hospital-acquired Bacterial Pneumonia (HABP) | Phase 2 | Recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 60 | 2026-03-25 | 2026-08-12 |
| Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam) - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 80 | 2025-04-12 | 2025-07-30 |
| A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia HRS-8427, Meropenem - Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 120 | 2025-04-10 | 2026-10-22 |
Sepsis (1)
Infections (1) · Inflammation (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Systemic Inflammatory Response Syndrome (1)
Meropenem (2) · Colistin (1) · Injections (1) · Polymyxin B (1) · avibactam, ceftazidime drug combination (1)
Jiangsu Aosaikang Pharmaceutical Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Nanjing Yoko Biomedical Co., Ltd. (1) · Qilu Pharmaceutical Co., Ltd. (1)
China (3)